Acute Coronary Syndromes

Acute coronary syndrome (ACS) is most commonly caused by a heart attack (myocardial infarction) where blood flow to the heart is suddenly blocked. This is usually caused by a blood clot from a ruptured coronary artery atherosclerotic plaque. Other causes include spontaneous coronary artery dissection (SCAD), which most commonly occurs in women. ACS is usually treated in a cath lab with angioplasty and the placement of a stent to prop the vessel open.

Thumbnail

CDC: 2 of 3 heart attack patients spurn rehab

Despite proven survival benefits, roughly two-thirds of heart attack patients forego cardiac rehabilitation, according to a report from the Centers for Disease Control and Prevention (CDC).

Thumbnail

Does public awareness of CPR, AEDs reduce response time to cardiac arrest?

National organizations, state governments and local communities have attempted to battle out-of-hospital cardiac arrest (OHCA) by supporting public awareness and improving preparedness, most notably through CPR training and use of automated external defibrillators (AEDs). A recent study—published online July 31 in Resuscitation, the journal of the European Resuscitation Council—examined the effectiveness of the Minnesota Heart Safe Communities program.

Study confirms effectiveness of new-generation heart stents in women

New-generation drug-eluting stents (DES) demonstrate long-term safety in women with acute myocardial ischemia (MI), with increased benefits for more severe cases of acute coronary syndrome (ACS), according to a new study.

Local gene therapy improves myocardial blood flow in refractory angina patients

For the first time, researchers have employed local gene therapy to boost myocardial blood flow in areas that have impaired perfusion reserves. They have also determined that elevated plasma Lp(a) can serve as a biomarker to identify those individuals with refractory angina (RA) who can benefit from the experimental therapy, gene transfer of VEGF-DΔNΔC.

Adults with acute coronary syndrome in registry differ from those in clinical trial

A registry analysis found that approximately one-third of patients who currently have acute coronary syndrome would have qualified for the IMPROVE-IT trial, which enrolled patients between 2005 and 2010.

Cardiovascular societies release AUC for revascularization in patients with ACS

Several medical societies recently released updated appropriate use criteria (AUC) for coronary revascularization in patients with acute coronary syndromes (ACS).

Around the web

GE HealthCare said the price of iodine contrast increased by more than 200% between 2017 to 2023. Will new Chinese tariffs drive costs even higher?

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.